Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Oliver Luxxe Assets LLC lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange ...

It's important to keep in mind that Buffett's words and actions don't always follow the path of the majority. This top ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Pfizer Inc. (NYSE:PFE – Get Free Report) traded up 0.4% during trading on Wednesday . The stock traded as high as $26.65 and ...

Check the time stamp on this data. Updated AI-Generated Signals for Pfizer Inc. (PFE) available here: PFE.

A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes ...

NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed ...